Lyme Vaccine Delivers Promising 70%+ Protection in Major Trial, Heads to FDA Review
TL;DR
Pfizer and Valneva’s VALOR Phase III trial for PF-07307405 shows about 73% efficacy at preventing confirmed Lyme disease, but the primary endpoint's 95% confidence interval is wide (15.8%–93.5%), likely due to milder Lyme activity during the study; a separate analysis confirms the lower bound above 20%, supporting FDA-approval steps. The vaccine targets the OspA protein to block Borrelia burgdorferi in ticks, and if approved could significantly boost Lyme prevention for high-risk groups.
- Finally, Some Good News in the Fight Against Lyme Disease Gizmodo
- Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal NBC News
- Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss CNBC
- Mixed results for Lyme disease vaccine hit Valneva shares Yahoo Finance
- Companies testing new Lyme disease vaccine to seek federal approval Newsday
Want the full story? Read the original reporting
Read on Gizmodo